5.4.9.5Vertical

Specialty Drug Distribution

Distributors managing specialty biologic and high-cost drug distribution.

Market snapshot

These figures describe Pharmaceutical & Drug Distribution (5.4.9), the segment that Specialty Drug Distribution sits within. They are not figures for Specialty Drug Distribution on its own.

Market size
~$1.28T
Growth
~6.6%CAGR (2017–22, nominal)
Companies
~7,012 firms
Firms by employee count

81.7% of firms have fewer than 20 employees: 5,729 micro-businesses, below most mandates.

The investable universe1,283 firms with 20+ employees
20–99
79862%
100–499
27421%
500+
21116%

Three companies move the overwhelming majority of pharmaceuticals, on gross margins around two percent, making this the most consolidated channel in American distribution. The revenue figure is therefore close to meaningless as a market opportunity; what is acquirable sits in specialty, compounding and long-term-care pharmacy distribution, not in the mainline channel.

NAICS 424210. U.S. Census Bureau, 2022 Statistics of U.S. Businesses; U.S. Census Bureau, 2022 Economic Census.

Business model & economics

Revenue model

Drug resale at very thin margins on enormous volume

Key economics

Revenue per firm
$182,678,078
Revenue per employee
$4,158,014
Employees per firm
44.4
Recurring revenue
High

recurring pharmacy/provider supply

EBITDA margin
Very thin

~1–2% gross distribution margins

Capex intensity
Low

Characteristics

  • Scale-driven: payroll is only 3% of revenue, so the cost base is assets, not headcount
  • Deep strategic-buyer pool: 211 firms exceed 500 employees, so a scaled asset has trade buyers
  • An oligopoly of McKesson, Cencora, and Cardinal.
  • Razor-thin margins on enormous volume.
  • Specialty-pharma distribution the higher-margin growth area.

NAICS 424210. U.S. Census Bureau, 2022 Statistics of U.S. Businesses; U.S. Census Bureau, 2022 Economic Census.

Geographic concentration

AlabamaAlaskaArizonaColoradoFloridaGeorgiaIndianaKansasMaineMassachusettsMinnesotaNorth CarolinaNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasDelawareDistrict of ColumbiaHawaiiIowaKentuckyMarylandMichiganMississippiMontanaNew HampshireOhioOregonTennesseeUtahVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoVermontLouisianaRhode IslandNew JerseyCaliforniaNew YorkNevada

New Jersey is more than twice as concentrated as the country, on the pharmaceutical corridor and the port that serves it; Nevada reflects national distribution centers placed for next-day reach rather than local demand.

New JerseyNevadaCaliforniaNew York

U.S. Census Bureau, 2022 Statistics of U.S. Businesses (firms by state), NAICS 424210. Concentration shown by location quotient.

M&A deal context

Deal activityModerate

Who’s acquiring

  • The big-three distribution strategics
  • Specialty-pharma distribution acquirers
  • Vertical (pharmacy/provider) integrators

What’s driving deals

  • Specialty and cold-chain pharma growth.
  • Vertical integration with pharmacy and providers.
  • Scale and logistics efficiency.

Find Specialty Drug Distribution acquisition targets

Search Acquisera’s index for companies classified under Specialty Drug Distribution (5.4.9.5) and build a targeted deal pipeline.

Search companies